Name: Transparent Stock Valuation Data (English & German)
Creator: JVInvest
License: https://creativecommons.org/licenses/by/4.0/

Question 1

Is JVInvest stock valuation data free and transparent?

Accepted Answer

Yes, all valuation data on JVInvest is 100% free and transparent. We provide verifiable P/E ratios for the Top 100 global stocks, S&P 500, Nasdaq 100, and major indices worldwide. All data sources are disclosed so you can verify every calculation yourself.

Question 2

What valuation metrics are available on JVInvest?

Accepted Answer

JVInvest provides transparent P/E ratios for Top 100 global stocks (MSCI World), S&P 500, Nasdaq 100, DAX, FTSE 100, Nikkei 225 and more. All valuation metrics are verifiable with disclosed quarterly EPS data and market prices.

Question 3

Do I need to create an account to access the data?

Accepted Answer

No account or signup is required. All S&P 500 fundamental data is freely accessible without registration.

Question 4

How can I verify the P/E ratio calculations?

Accepted Answer

All our valuation data is 100% transparent. We disclose all data sources, quarterly EPS figures, and market prices used in calculations. You can verify every P/E ratio yourself using our transparent methodology.

Question 5

What is a Sankey chart for stocks?

Accepted Answer

A Sankey chart visualizes the flow of money through a company's financial statements - showing how revenue flows to costs, operating income, net income, and cash flows. JVInvest offers free Sankey charts for all S&P 500 companies.

Question 6

Which stock indices have free valuation data?

Accepted Answer

JVInvest provides free, verifiable valuation data for major global indices: S&P 500, Nasdaq 100, DAX 40, FTSE 100, CAC 40, Nikkei 225, and the Top 100 MSCI World stocks. All index P/E ratios are calculated transparently.

Question 7

What is the current S&P 500 P/E ratio?

Accepted Answer

JVInvest calculates and displays the current S&P 500 index P/E ratio based on the aggregate earnings of all constituent companies. Visit the Valuation page for the latest P/E ratio data.

Umsatz	58.74 USD bn
Bruttoergebnis	48.12 USD bn
Operatives Ergebnis	13.75 USD bn
Nettogewinn	10.22 USD bn
Nettomarge	17.4 %

Oncology	23.70 USD bn
Cardiovascular, Renal & Metabolism	12.76 USD bn
Respiratory & Immunology	8.17 USD bn
Vaccines & Immune Therapies	846 USD m
Rare Disease	9.13 USD bn
Other	972 USD m
Alliance Revenue	3.07 USD bn
Collaboration Revenue	99 USD m

AstraZeneca PLC (AZN) Aktie: Umsatz, Gewinn, Margen & Bewertung

AstraZeneca PLC Kennzahlen (FY 2025)

AstraZeneca PLC Umsatz nach Segmenten

Geschäftsmodell von AstraZeneca PLC

Weitere Aktienanalysen wie AstraZeneca PLC